Monday | The Hindu
Ranbaxy to make presence in African region
CHENNAI: Daiichi Sankyo Company and Ranbaxy Laboratories have announced that Ranbaxy will launch Olmesartan Medoxomil, an anti-hypertensive, originally discovered by Daiichi Sankyo in six African countries.
Ranbaxy arm set to shed Orchid stake
R Ravichandran Posted: Thursday, Dec 17, 2009 at 0406 hrs IST Updated: Thursday, Dec 17, 2009 at 0406 hrs IST Chennai: Solrex Pharmaceuticals, a wholly owned subsisidiary of Ranbaxy Laboratories, is planning to exit Chennai-based Orchid Chemicals & Pharmaceuticals Ltd, in which it holds little over 13.7% stake.
Fortis in talks to buy Lanka hospital chain
Move comes within months of acquiring Wockhardt hospitals. Fortis Healthcare, a hospital chain promoted by former Ranbaxy owners Malvinder Mohan Singh and Shivinder Mohan Singh, is close to a major acquisition overseas.
Ranbaxy ends JV with Japanese firm
Pharma company Ranbaxy Laboratories on Tuesday said it has exited from Japan-based joint venture company--Nihon Pharmaceutical Industry.
'China will snatch our market from us'
Atul Sobti took over as the chief executive officer and managing director at Ranbaxy Laboratories, six months ago.
The Financial Express Posted: Saturday, Nov 21, 2009 at 0050 hrs IST Updated: Saturday, Nov 21, 2009 at 0050 hrs IST : Ranbaxy recalls drugs from US market Ranbaxy Laboratories has recalled from the US market a batch of 4,348 cartons of Sotret Isotretinoin capsules used in treating skin infections.
Issues with USFDA to take long to resolve: Ranbaxy
Drug Administration to sort out issues related to generic drugs but the matter is likely to take long to resolve.
NEW DELHI: Riding on the back of consistent sales in emerging markets and cost cutting measures, Ranbaxy Laboratories on Monday posted a consolidated profit after tax of Rs.
Badal asks Ranbaxy to add booster dose to state healthcare
Chandigarh: Punjab chief minister Parkash Singh Badal has asked Ranbaxy Laboratories Limited to prepare a comprehensive plan to undertake extensive research to study the root cause of the deadly diseases and suggest measures for their effective eradication to make Punjab, a disease-free state.
Pfizer may make counter bid for Ranbaxy
Pfizer may bid for Ranbaxy Laboratories, countering a $4.6 billion offer by Japan's Daiichi Sankyo for the Indian generic drug maker, the Business Standard newspaper said.
EU anti-trust raid on Ranbaxy France unit
New Delhi After facing a slew of troubles in the US market last year, the country's largest drug maker, Ranbaxy Laboratories Ltd, in which Daiichi Sankyo of Japan has a 64% stake, is in for some rude shock in Europe.
Ranbaxy to market Daiichi's products in Mexico
The Gurgaon-based drug firm would market the products through its Latin America-based subsidiary, Ranbaxy Mexico SA de CV Mexico.
Ranbaxy to market Medy-Tox product
GURGAON: Ranbaxy Laboratories has entered into an in-licensing agreement with Medy-Tox, South Korea's Botulinum-Toxin specialised biotech venture, for the latter's cosmetic product, Neuronox.
Ranbaxy ties up with South Korean firm
Drug major Ranbaxy Laboratories has entered into a deal with South Korean biotech firm Medy-Tox for marketing its cosmetic product, Neuronox, in the Indian market.
Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of Evista in Romania
TOKYO, Gurgaon, India, September 1, 2009 - Daiichi Sankyo Company Limited and Ranbaxy Laboratories Limited announced today that Terapia S.A. , a subsidiary of Ranbaxy in Romania, will market the osteoporosis medication, Evista in Romania.
Flu vaccine flies off the shelves
With the government indicating on Monday that it would soon procure 20 million capsules of the generic antiviral drug Tamiflu in the wake of the spread of swine flu, drug makers across the country including Ranbaxy, Cipla, Hetero and Roche are bracing themselves for a hike in production of the in-demand drug.
Swine flu bolsters Indian pharma stocks
Shares of Indian drug firms that make the generic version of Roche's Tamiflu, used to treat H1N1 flu, rose 5-19 per cent on Tuesday as the death toll from the pandemic in the country rose to ten.
India's Ranbaxy's Q2 profit soars but sees year loss
Top Indian generic drugs firm Ranbaxy Laboratories, a unit of Japan's Daiichi Sankyo, reported Friday net profit soared during the second quarter, swelled by foreign exchange gains.
Ranbaxy to market cholesterol-lowering drug in Canada
Ranbaxy Laboratories has received a final approval from from Health Canada, therapeutic products directorate to manufacture and market Ran-Simvastatin tablets in Canada.
Dr Reddy's eyes prime position in US generics
Mumbai, May 31: Hyderabad-based Dr Reddy's Laboratories Ltd aims to be among the top five generic companies in the US by 2013, banking on an array of new drugs for which it is seeking permissions from American authorities.
Also on Topix